QCMD
SARS-CoV-2 (COVID-19) Antigen Testing Pilot Study
Randox, in partnership with QCMD, is pleased to announce a new QCMD EQA pilot study for SARS-CoV-2 (COVID-19) Antigen Testing. This new pilot is designed to evaluate a laboratory’s ability to detect SARS-CoV-2 (COVID-19) antigen and will provide an opportunity to assess performance against an international peer group.
QCMD is a world leading EQA / Proficiency Testing (PT) provider, dedicated to improving the quality of molecular diagnostic assays used in the detection of infectious diseases. With an extensive database of over 10,000 participants in over 100 countries, QCMD is one of the largest providers of molecular EQA in the fi eld of infectious disease testing.
Features & Benefits
- Smart-Phone App Results Submission
Results can be returned via a smart-phone app so that participants using lateral flow devices can provide pictures of their device/result with the phone camera.
- Comprehensive Reports
A real-time rapid report will be provided on submission of results. An individual report is received after each challenge, summarising laboratory performance in comparison to an international peer group.
- EQA Management System
IT EQA Management System (ITEMS) provides an online tool to easily manage all EQA activities from programme registration to submission of results and provision of EQA reports.
- Not infectious
Samples containing SARS-CoV-2 antigens are inactivated and not infectious ensuring safe handling of material.
- Suitable for Point of Care
Samples are supplied liquid ready-to-use ensuring they are ideal for use at the point care.
Specification
Target Range – Covers the clinical range
Matrix – Universal p9 virusPHIX sample stabilisation buffer
Sample Format – Eluted swab samples with a buffer
Analysis Type – Qualitative
Shipping Conditions – Ambient
Format – Liquid ready-to-use
Ordering Information
| Catalogue Number | Challenges | Samples per Challenge | Distribution / Testing Period |
|---|---|---|---|
| QAS214224 | 3 | 3 | Q2, Q3, Q4 |
